trending Market Intelligence /marketintelligence/en/news-insights/trending/DozGoAb4mGmLG6JF1qCY8Q2 content esgSubNav
In This List

Japan approves Takeda's multiple myeloma treatment

Blog

Insight Weekly: US inflation soars; real estate faces slowdown; megadeals drive tech M&A

Blog

Commercial Banking: June 22nd Edition

Blog

Understanding Loss Given Default A Review of Three Approaches

Blog

Insight Weekly: Path to net-zero; US manufacturing momentum; China's lithium M&A frenzy


Japan approves Takeda's multiple myeloma treatment

The Japanese Ministry of Health, Labour and Welfare approved Takeda Pharmaceutical Co. Ltd.'s Ninlaro capsules for the treatment of multiple myeloma, a cancer of plasma cells.

Ninlaro is indicated in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma who have not responded to standard therapy or who have relapsed after treatment.

The approval is based on a phase 3 trial which demonstrated that the combination treatment increased median progression-free survival by about 6 months or 40% compared to placebo, lenalidomide, and dexamethasone.